ES2059990T3 - Procedimiento de preparacion de un producto antimicrobiano en particulas, producto antimicrobiano obtenido y aplicaciones. - Google Patents

Procedimiento de preparacion de un producto antimicrobiano en particulas, producto antimicrobiano obtenido y aplicaciones.

Info

Publication number
ES2059990T3
ES2059990T3 ES90200971T ES90200971T ES2059990T3 ES 2059990 T3 ES2059990 T3 ES 2059990T3 ES 90200971 T ES90200971 T ES 90200971T ES 90200971 T ES90200971 T ES 90200971T ES 2059990 T3 ES2059990 T3 ES 2059990T3
Authority
ES
Spain
Prior art keywords
antimicrobial product
layer
preparation
applications
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90200971T
Other languages
English (en)
Inventor
Daniel Samain
Frederique Nguyen
Michel Francois Degre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio Serae Laboratoires SA
Original Assignee
Bio Serae Laboratoires SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Serae Laboratoires SA filed Critical Bio Serae Laboratoires SA
Application granted granted Critical
Publication of ES2059990T3 publication Critical patent/ES2059990T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
    • A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
    • A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
    • A23L3/3463—Organic compounds; Microorganisms; Enzymes
    • A23L3/3571—Microorganisms; Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

LA INVENCION SE REFIERE A UN PROCEDIMIENTO PARA LA OBTENCION DE UN PRODUCTO PARTICULAR ANTIMICROBIANO A PARTIR DE UN SISTEMA LP ENZIMA LACTOPEROXIDASA/DONADOR DE OXIGENO/EVENTUALMENTE SUBSTRATO OXIDABLE. EL PROCEDIMIENTO CONSISTE EN FONDEAR EL ENZIMA LACTOPEROXIDASA EN UN VECTOR PARTICULAR QUE CONTIENE UNA RED POLISACARIDA, UNA PRIMERA CAPA LIPIDA Y UNA SEGUNDA CAPA FOSFOLIPIDA, DE MODO QUE LAS MOLECULAS DE ENZIMA ESTAN INSERTADAS EN ESTA SEGUNDA CAPA Y/O EN LA PRIMERA. EL PRODUCTO DE ACUERDO CON LA INVENCION SE OBTIENE CONDICIONANDO DESPUES EN MEDIO NO ACUOSO EL VECTOR PARTICULAR PRECITADO Y LAS MOLECULAS DEL SISTEMA LP NO INTEGRADAS EN DICHO VECTOR. EL PROCEDIMIENTO DE LA INVENCION PERMITE AJUSTAR LA DIFUSIBILIDAD DEL PRODUCTO Y SU MOVILIDAD EN FUNCION DE LAS APLICACIONES, SIN DESNATURALIZACION DEL SISTEMA LP
ES90200971T 1989-05-12 1990-04-19 Procedimiento de preparacion de un producto antimicrobiano en particulas, producto antimicrobiano obtenido y aplicaciones. Expired - Lifetime ES2059990T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8906668A FR2646777B1 (fr) 1989-05-12 1989-05-12 Procede de preparation d'un produit particulaire antimicrobien, produit antimicrobien obtenu et applications

Publications (1)

Publication Number Publication Date
ES2059990T3 true ES2059990T3 (es) 1994-11-16

Family

ID=9381881

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90200971T Expired - Lifetime ES2059990T3 (es) 1989-05-12 1990-04-19 Procedimiento de preparacion de un producto antimicrobiano en particulas, producto antimicrobiano obtenido y aplicaciones.

Country Status (9)

Country Link
US (1) US5206156A (es)
EP (1) EP0397227B1 (es)
JP (1) JP3003045B2 (es)
KR (1) KR0149997B1 (es)
AT (1) ATE96680T1 (es)
CA (1) CA2014847C (es)
DE (1) DE69004329T2 (es)
ES (1) ES2059990T3 (es)
FR (1) FR2646777B1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9002422D0 (en) * 1990-02-03 1990-04-04 Boots Co Plc Anti-microbial compositions
JP4063317B2 (ja) 1991-02-21 2008-03-19 エクソゼミス，インコーポレイテッド 感染治療および叢制御の方法および組成物
US5565197A (en) * 1991-02-21 1996-10-15 Exoxemis, Inc. Method which utilizes a haloperoxidase composition to inhibit the growth of microorganisms which cause sexually transmitted diseases
US5888505A (en) * 1991-02-21 1999-03-30 Eoe, Inc. Method for selectively inhibiting the growth of microbes using a haloperoxidase-halide-peroxide system
US5756090A (en) * 1991-02-21 1998-05-26 Eoe, Inc. Oxygen activatable formulations for disinfection or sterilization
US5389369A (en) * 1991-02-21 1995-02-14 Exoxemis, Inc. Halo peroxidase containing compositions for killing yeast and sporular microorganisms
US5534501A (en) * 1991-06-04 1996-07-09 A Et S Biovecteurs Particle for use as a milk fat globule substitute, composition containing same and process for the preparation of said particle
US5736371A (en) * 1991-06-04 1998-04-07 A Et S Biovecteurs Biodegradable particulate vector for transporting molecules having biological activity
FR2677249B1 (fr) * 1991-06-04 1995-03-17 Biovecteurs As Vecteur particulaire biodegradable et procede de synthese.
FR2677272B1 (fr) * 1991-06-05 1995-03-03 Biovecteurs As Vecteur particulaire a tropisme selectif, procede de preparation et composition pharmaceutique.
US5747078A (en) * 1991-06-11 1998-05-05 Gist-Brocades, N.V. Longterm antimicrobial activity obtained by sustained release of hydrogen peroxide
AU652279B2 (en) * 1991-06-11 1994-08-18 Dsm Ip Assets B.V. Sustained release of hydrogen peroxide
GB9200891D0 (en) * 1992-01-16 1992-03-11 Mann Stephen P Formulation of microorganisms
AU665381B2 (en) * 1992-01-23 1996-01-04 Morinaga Milk Industry Company Limited Antibacterial agent and treatment of article therewith
FR2695034B1 (fr) 1992-09-01 1994-10-07 Oreal Composition cosmétique ou pharmaceutique comprenant en association une peroxydase et un agent anti-oxygène singulet.
RU2160990C2 (ru) * 1994-07-14 2000-12-27 Новартис А.Г. Гранулированный состав, содержащий микроорганизмы, способ его приготовления и его применение
CA2230160A1 (en) 1995-08-23 1997-03-06 The University Of British Columbia Antimicrobial cationic peptides and methods of screening for the same
SE506529C2 (sv) * 1996-01-23 1997-12-22 Semper Ab Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori
FR2750575B1 (fr) * 1996-07-04 1998-11-13 Labeyrie Sa Procede de decontamination de produits d'origine aquacole
AU4958700A (en) * 1999-05-14 2000-12-05 Tatua Co-operative Dairy Company Limited, The Microbially resistant compositions
US6172040B1 (en) * 1999-05-28 2001-01-09 A. Satyanarayan Naidu Immobilized lactoferrin antimicrobial agents and the use thereof
FR2825373B1 (fr) 2001-05-31 2004-04-30 Tmi Europ Procede de production enzymatique d'un agent de traitement a l'etat fluide
WO2005085287A1 (en) * 2004-03-03 2005-09-15 En-N-Tech, Inc. Treatments for contaminant reduction in lactoferrin preparations and lactoferrin-containing compositions
CN1719003B (zh) 2004-07-07 2010-05-26 株式会社东芝 用于汽轮机的主汽阀
US8945540B2 (en) * 2008-05-09 2015-02-03 Exoxemis, Inc. Compositions for enhancing the antibacterial activity of myeloperoxidase and methods of use thereof
CA2839747A1 (en) 2011-07-11 2013-01-17 Exoxemis, Inc. Eosinophil peroxidase compositions and methods of their use
WO2015018739A1 (en) * 2013-08-06 2015-02-12 Bienca N.V. Antimicrobial compositions and use thereof in food preservation
GB201417248D0 (en) * 2014-09-30 2014-11-12 Blueberry Therapeutics Ltd Compostion and methods of treatment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE23523E (en) * 1952-07-22 Enzymaticaiay deoxygenated
US2765233A (en) * 1953-05-29 1956-10-02 Sarett Enzyme-treated sheet product and article wrapped therewith
US3242051A (en) * 1958-12-22 1966-03-22 Ncr Co Coating by phase separation
US4233290A (en) * 1979-03-01 1980-11-11 Spa-Societa Prodotti Antibiotici, S.P.A. Method of treating domestic animals
US4486408A (en) * 1981-04-07 1984-12-04 Kiel Johnathan L Insoluble crosslinked cytotoxic oxidase-peroxidase system
LU85910A1 (fr) * 1985-05-22 1986-12-05 Oleofina Sa Procede pour eliminer l'oxygene dans les aliments et les boissons,et composition enzymatique utilisee a cet effet
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
FR2600250B1 (fr) * 1986-06-23 1989-11-24 Bio Serae Procede pour conditionner une composition antibacterienne et composition antibacterienne conditionnee
IT1197924B (it) * 1986-10-28 1988-12-21 Prodotti Antibiotici Spa Procedimento per la preparazione di alimenti di origine animale
SE8701839L (sv) * 1987-05-05 1988-11-06 Ewos Ab Livs- och fodermedel
JPS6447364A (en) * 1987-08-17 1989-02-21 Suntory Ltd Food and drink containing lactate monooxygenase
JPH0262829A (ja) * 1988-05-18 1990-03-02 Nippon Kayaku Co Ltd 虚血に基づく傷害の予防及び治療剤
FR2631826B1 (fr) * 1988-05-27 1992-06-19 Centre Nat Rech Scient Vecteur particulaire utile notamment pour le transport de molecules a activite biologique et procede pour sa preparation

Also Published As

Publication number Publication date
JP3003045B2 (ja) 2000-01-24
CA2014847A1 (fr) 1990-11-12
FR2646777B1 (fr) 1993-09-03
ATE96680T1 (de) 1993-11-15
US5206156A (en) 1993-04-27
DE69004329D1 (de) 1993-12-09
DE69004329T2 (de) 1994-05-19
CA2014847C (fr) 2000-06-13
KR0149997B1 (ko) 1998-10-15
KR900017571A (ko) 1990-12-19
EP0397227A1 (fr) 1990-11-14
EP0397227B1 (fr) 1993-11-03
JPH03193708A (ja) 1991-08-23
FR2646777A1 (fr) 1990-11-16

Similar Documents

Publication Publication Date Title
ES2059990T3 (es) Procedimiento de preparacion de un producto antimicrobiano en particulas, producto antimicrobiano obtenido y aplicaciones.
Rao et al. Encapsulation of antioxidant peptide enriched casein hydrolysate using maltodextrin–gum arabic blend
Cian et al. Bioactive Phaseolus lunatus peptides release from maltodextrin/gum arabic microcapsules obtained by spray drying after simulated gastrointestinal digestion
AU4879396A (en) Use of inorganic aerogels in pharmacy
CA2327522A1 (en) Incorporation of active substances in carrier matrixes
DE59404366D1 (de) Mehrenzymgranulat
ATE311894T1 (de) Verfahren zur herstellung von konditionierten zellkulturmedium-zusammensetzungen
ATE159284T1 (de) Feuchttigkeitsbeständige zusammensetzung
EP1364585A4 (en) SOYBEAN PROTEIN, METHOD FOR THE PRODUCTION THEREOF, AND SOUR PROTEIN FOODS CONTAINING THEREOF
AU650821B1 (en) Enteral nutritional product
ATE227427T1 (de) Verfahren zur lagerung labiler proteine
FI953442A (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
WO1996034113A3 (en) Methods for the identification of farnesyltransferase inhibitors
DE69632638D1 (de) Mikrogranulaten zur nahrungs- oder futteranwendung
DE59610633D1 (de) Medikament, insbesondere zur modulation der immunantwort bei der bekämpfung von viren, tumoren, bakterien und parasiten
AU6228300A (en) Modification of foaming properties of proteins
PT1244472E (pt) Composicao vitaminica em particulas
Li et al. Milk protein hydrolysates obtained with immobilized alcalase and neutrase on magnetite nanoparticles: Characterization and antigenicity study
ES2045766T3 (es) Corteza de zaragatona (psyllium) que contiene un acido comestible.
WO2000018909A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(CENARCHAEUM SYMBIOSUM)
DK0740547T3 (da) Liposomer indeholdende deri indkapslede proteiner, fremgangsmåde til deres fremstilling, samt farmaceutiske og kosmetiske p
WO1999038821A3 (fr) Composes transfectants sensibles aux conditions reductrices, compositions pharmaceutiques les contenant, et leurs applications
AU4104800A (en) Universal camouflage material for camouflage clothing and for camouflage
WO2003060067A3 (en) P85-alpha nucleic acids, polypeptides and related methods
Huber et al. The role of macrophages as effector cells

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 397227

Country of ref document: ES